SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors
October 23, 2023 07:45 ET
|
BeyondSpring, Inc.
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- SEED Therapeutics (SEED), an innovative global biotech company focused on engineering “molecular glues” and harnessing its targeted protein degradation...
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
October 04, 2023 15:55 ET
|
BeyondSpring, Inc.
NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking...
BeyondSpring and Leading Cancer Center to Present Poster at SITC’s 38th Annual Meeting
September 27, 2023 10:00 ET
|
BeyondSpring, Inc.
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking...
BeyondSpring to Participate in the R.W. Baird’s 2023 Global Healthcare Conference
September 07, 2023 08:00 ET
|
BeyondSpring, Inc.
NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking...
SEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors
June 20, 2023 08:00 ET
|
BeyondSpring, Inc.
Former Director at Eli Lilly, HSBC and MastercardBrings Almost Five Decades of Experience in Finance, Strategy and Risk Governance NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- SEED Therapeutics (the...
BeyondSpring and Leading Cancer Center Present Poster Highlighting Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCT
June 07, 2023 08:00 ET
|
BeyondSpring, Inc.
NEW YORK, June 07, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking...
BeyondSpring and Leading Cancer Center to Present Poster at 2023 ASCO Annual Meeting
May 18, 2023 08:30 ET
|
BeyondSpring, Inc.
NEW YORK, May 18, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking...
BeyondSpring Provides Business Update and Reports Year End 2022 Financial Results
April 18, 2023 16:30 ET
|
BeyondSpring, Inc.
- SEED Therapeutics, a BeyondSpring Subsidiary, Achieved Milestones on the Eli Lilly Collaboration - BeyondSpring Completed Enrollment of Three Investigator-Initiated Trials (IIT) with Plinabulin...
BeyondSpring Files 2022 Annual Report on Form 20-F
April 18, 2023 16:30 ET
|
BeyondSpring, Inc.
NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a clinical-stage global biopharmaceutical company focused on using its novel...
BeyondSpring Enrolls First Patient in Phase 2 Study with Plinabulin, Keytruda and Docetaxel in Patients with Metastatic Non-Small Cell Lung Cancer Who Progressed After Immunotherapy
March 01, 2023 08:00 ET
|
BeyondSpring, Inc.
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative...